A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
Semaglutide cuts risk for kidney outcomes, death in CKD with T2DM
May 31, 2024
A reduction was seen in risk for clinically important kidney outcomes and death from cardiovascular causes.
Antibiotics not helpful for cough due to lower respiratory tract infection
Apr 25, 2024
Despite patient beliefs, no effect was seen on the severity or duration of the cough.
ACP: Recommendations developed for newer type 2 diabetes medications
Apr 22, 2024
A strong recommendation was given for the addition of an SGLT-2 or GLP-1 agonist to metformin, and lifestyle modifications.
ACP: Next-generation antibiotics underused for gram-negative infections
Apr 22, 2024
41.5% of difficult-to-treat resistance episodes were treated exclusively with traditional agents.
2011 to 2020 saw increase in annual prescription meds expenditures
Apr 15, 2024
Metabolic agents were the most costly category; antidiabetic agents were the mostly costly therapeutic area.
One in seven drug supply chain issue reports tied to drug shortages
Apr 10, 2024
Supply disruptions increased for drugs with and without reports at the start of the COVID-19 pandemic.
ACC: Semaglutide beneficial in obesity-related heart failure, type 2 diabetes
Apr 09, 2024
Larger reductions were seen in heart failure-related symptoms and physical limitations for patients with HFpEF and type 2 diabetes.
Nirmatrelvir-ritonavir does not speed up alleviation of COVID-19 symptoms
Apr 05, 2024
The time to sustained alleviation of COVID-19 symptoms was not significantly shorter with nirmatrelvir-ritonavir versus placebo.
Lixisenatide reduces motor disability progression in Parkinson’s disease
Apr 04, 2024
Lixisenatide results in less progression of motor disability than placebo at 12 months for individuals with early Parkinson’s disease.